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Abstract 
Amphibian skin has proved repeatedly to be a largely untapped source of bioactive peptides and 
this is especially true of members of the Phyllomedusinae subfamily of frogs native to South and 
Central America. Tryptophyllins are a group of peptides mainly found in the skin of members of 
this genus. In this study, a novel tryptophyllin (TPH) type 3 peptide, named AcT-3, has been iso-
lated and structurally-characterised from the skin secretion and lyophilised skin extract of the 
red-eye leaf frog, Agalychnis callidryas. The peptide was identified in and purified from the skin 
secretion by reverse-phase HPLC. MALDI-TOF mass spectrometry and MS/MS fragmentation 
sequencing established its primary structure as: pGlu-Gly-Lys-Pro-Tyr-Trp-Pro-Pro-Pro-Phe- 
Leu-Pro-Glu, with a non-protonated molecular mass of 1538.19Da. The mature peptide possessed 
the canonical N-terminal pGlu residue that arises from post-translational modification of a Gln 
residue. The deduced open-reading frame consisted of 63 amino acid residues encoding a high-
ly-conserved signal peptide of approximately 22 amino acid residues, an intervening acidic spacer 
peptide domain, a single AcT-3 encoding domain and a C terminal processing site. A synthetic 
replicate of AcT-3 was found to antagonise the effect of BK on rat tail artery smooth muscle and 
to contract the intestinal smooth muscle preparations. It was also found that AcT-3 could 
dose-dependently inhibit the proliferation of human prostate cancer cell lines after 72h incubation. 
Key words: Agalychnis callidryas, proline-rich peptide, bradykinin antagonist, anticancer effect, myotropic ac-
tivities 
Introduction 
Amphibians are one of the most wide-
ly-distributed vertebrate groups in the world, ranging 
from inside the Arctic Circle in the North to southern 
Chile and the Patagonian grasslands of southern Ar-
gentina [1]. The ability of amphibians to survive in 
such a broad diversity of habitat types is close-
ly-related to their highly-adapted skins, which are 
highly-permeable to water and fulfilled many differ-
ent morphological, physiological and biochemical 
functions [2]. Skin secretions of the dorsal glands of 
amphibians provide rich chemical arsenals of 
host-defence compounds that are not just confined to 
acting in the animal’s defence system against micro-
organisms and predators, but are also involved in the 
regulation of dermal physiological actions [3]. There 
are two major types of glands in the amphibian skin, 
mucous and granular glands. Mucous glands secrete a 
transparent mucus secretion that helps to keep the 
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skin moist and prevents mechanical damage to the 
delicate skin [4]. Granular glands produce a secretion 
containing various chemical compounds including 
peptides, alkaloids, biogenic amines and steroids [5, 
3]. 
The peptides discovered in frog skin secretions 
exhibit a wide range of biological activities, such as 
antimicrobial, anti-viral, anti-tumour, insu-
lin-releasing, analgesic, vasodilatation and immuno-
modulatory properties [6-10]. These peptides are po-
tent resources for drug development. There are two 
extensively-used procedures for isolating frog skin 
peptides. The first, carried out in the early research 
years, involves killing frogs and extracting their dried 
excised skins with an organic solvent, such as meth-
anol [11]. The second and more modern and ethical 
method, collects the frog skin secretions directly from 
the skin surface following stimulation of their release 
by a pharmacological mediator (such as adrenaline) or 
by non-invasive electrical shock to the animal [12]. 
After secretion acquisition, the compounds within are 
isolated by ion-exchange chromatography or re-
versed-phase high performance liquid chromatog-
raphy. The separated bioactive peptides can then be 
assayed with a battery of bioassays, such as pharma-
cological assay, bactericidal assay, anti-cancer assay, 
insulin-releasing assay etc. [5].  
The subfamily of South and Central American 
leaf frogs, the Phyllomedusinae, contains three 
well-known genera, Phyllomedusa, Agalychnis and 
Pachymedusa. Phyllomedusine species contain huge 
amounts of diverse biologically-active peptides that 
include both neuropeptide analogues with pharma-
cological activity and an abundance of several differ-
ent classes of broad-spectrum antimicrobial peptides. 
Erspamer once described the skins of members of the 
Phyllomedusinae frog sub-family as “huge storehouses 
of bioactive peptides” [13]. These active peptides are 
generally divided into eight distinct families: Caeru-
leins-the representative peptide from this family be-
ing phyllocaerulein from P. sauvagei, this peptide 
family exhibits a spectrum of activity similar to those 
of the mammalian intestinal hormones gastrin and 
cholecystokinin [14]. Bradykinins-a large number of 
bradykinins and phyllokinins have been found in the 
skin secretion of Phyllomedusa hypochondrialis-[Val]1, 
[Thr]6-bradykinyl-Gln, Ser had biological activity in 
cell cultures expressing the human bradykinin B2 re-
ceptor and in guinea pig ileum preparations [15]. 
Tachykinins-these neuropeptide analogues have high 
affinities for the mammalian tachykinin receptor 
subtypes P and K, and have been found in Agalychnis 
callidryas and P. bicolor [16]. Bombesins-while canoni-
cal bombesin is lacking in Phyllomedusa skin, its 
structural homologue, phyllolitorin, has been found 
in P. sauvagei, P. rohdei and P. burmeisteri skin [13]. 
Tryptophyllins-to date, more than 90% of the repre-
sentatives of this type of peptide have been reported 
from phyllomedusine skin [17-19]. Sauvagine-this 
peptide, with forty amino acid residues, was isolated 
from the skin of P. sauvagei. Sauvagine possesses a 
number of biological activities including hypotension, 
antidiuretic, hyperglycaemic and the effects on the 
anterior pituitary [13]. Dermorphins-these are selec-
tive opioid-receptor active peptides isolated from the 
skins of P. sauvagei and P. rohdei [13]. Dermasep-
tins-these have been reported from the skins of all 
phyllomedusines studied to date and these antimi-
crobial peptides have been shown to be effective kill-
ers of Gram-negative and Gram-positive bacteria and 
some fungi [20].  
Agalychnis callidryas is a widespread Central 
American leaf frog species belonging to the Phyl-
lomedusinae subfamily. A. callidryas is one of the 
world’s most beautifully-coloured amphibians and is 
distributed from Mexico to Panama, with an isolated 
report from the Cartagena Botanic Gardens in Co-
lombia. This species inhabits humid forests, primarily 
in lowlands and sometimes on premontane slopes up 
to 1250m [21]. Recent studies have shown that the 
peptides isolated from the skin of A. callidryas exhib-
ited a wide-spectrum of biological functions [22].  
Here, the isolation and structural elucidation of a 
novel tryptophyllin type-3 peptide (named AcT-3) 
from the red-eyed leaf frog, Agalychnis callidryas, uti-
lising a mass spectrometric and ‘shotgun’ cDNA se-
quencing, is described. The peptide was subsequently 
chemically-synthesised successfully using a PS3 sol-
id-phase synthesiser and bioassays with this synthetic 
replicate have shown that it is a non-competitive in-
hibitor of the effect of bradykinin on rat tail artery and 
a constrictor on rat small intestinal smooth muscle 
preparations. AcT-3 also has an anti-proliferative ef-
fect on several human prostate cancer cell lines.  
Materials and methods 
Acquisition of skin secretions 
Adult red-eye leaf frogs, Agalychnis callidryas, 
were obtained from commercial sources. The frogs 
(both sexes, snout-to-vent length 4-6cm) were main-
tained in a purpose-designed terrarium under a 
12h/12h light/dark cycle and were fed multivita-
min-loaded crickets every two days. Animals were 
kept under these conditions for at least 3 months prior 
to experimentation. Skin secretions were obtained 
from the dorsal skin by transdermal electrical stimu-
lation (6v DC, 4ms pulse width, 50HZ) through plat-
inum electrodes for two periods of 15s duration. The 
skin secretions were washed from the skin with de-
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ionised water, snap-frozen in liquid nitrogen, lyophi-
lised and stored at −20°C prior to analysis. 
Construction of a cDNA library from dried 
skin and subsequent “shotgun” cloning 
Pieces from four frog skins (total 56mg dry 
weight) were chopped into small pieces (1-2mm2) and 
transfered into 1mL of cell lysis solution at 4°C for 2h. 
Polyadenylated mRNA was isolated using magnetic 
oligo-dT beads as described by the manufacturer 
(Dynal Biotech, UK) and reverse-transcribed. Stand-
ard reverse transcriptase-PCR methods were used to 
synthesise the first-strand cDNA and this was carried 
out by using a SMART RACE cDNA Amplification 
Kit (BD CLONTECH, UK). RACE PCR was used to 
amplify sequences between a single previously char-
acterised region in the cDNA and an anchor sequence 
that was coupled to the 5′ or the 3′ end. Briefly, the 
3′-RACE reactions employed an NUP primer (sup-
plied with the kit) and a degenerate sense primer (S1: 
5′-ACTTTCYGAWTTRYAAGMSCARABATG-3′) that 
was designed to a highly-conserved domain of the 
5′-untranslated region of previously characterised 
skin peptide-encoding cDNAs from Phyllomedusa 
species. The PCR cycling procedure was set as fol-
lows: Initial denaturation step: 60s at 94°C; 35 cycles: 
denaturation 30s at 94°C; primer annealing for 30s at 
58°C; extension for 180s at 72°C. PCR products were 
purified, cloned using a pGEM-T vector system 
(Promega Corporation, UK) and then sequenced by 
ABI 3100 automated sequencer. All putative biologi-
cal peptide homologue structures deduced from 
cDNA clones were subjected to bioinformatic analysis 
using the BLAST program available on-line through 
the National Center for Biotechnology Information 
(NCBI), USA. 
Peptidomic analysis of defensive skin secretion 
For the purpose of isolating the functional pep-
tides from frog skin secretions, ten milligrams of ly-
ophilised pooled skin secretion of Agalychnis callidryas 
were dissolved in 1mL of 0.05% (v/v) TFA and clari-
fied of microparticulates by centrifugation (1500×g). 
The clear supernatant was decanted and pumped 
directly onto a reverse phase HPLC column and sub-
jected to LC/MS using a gradient formed from 
0.05/99.5 (v/v) TFA/water to 0.05/19.95/80.0 
(v/v/v) TFA/water/acetonitrile in 240 min at a flow 
rate of 1 mL/min. The sample was collected in one 
minute interval and each peak was included in one 
fraction or more fractions. A Thermoquest gradient 
reversed phase HPLC system, fitted with an analytical 
column (Phenomenex C-5, UK). The flow of effluent 
from the column was split, with 10% entering the 
mass spectrometer source and 90% was collected us-
ing an automated fraction collector. All the fractions 
were subjected to MALDI-TOF mass spectrometry on 
a linear TOF Voyager-DE mass spectrometer (percep-
tive Biosystems, USA) in order to determine the m/z 
values of the contents of each fraction. Then the pep-
tide with mass coincident with the putative bioactive 
peptide, as deduced from cloned precursor cDNAs, 
was subject to structural analysis by using MS/MS 
fragmentation sequencing on a Solarix FT-ICR-MS 
(Bruker Daltonics, USA). 
Synthesis of AcT-3 
AcT-3 was synthesized by solid-phase peptide 
synthesis methodology using a PS3 Automated Solid 
Phase Peptide synthesizer (Protein Technologies Inc., 
USA). Following deprotection and cleavage from the 
resin, the peptide was purified by reverse-phase 
HPLC. The purity and the structure of the final 
product were monitored by MALDI-TOF MS and 
Solarix FT-ICR-MS.  
Pharmacological characterization of AcT-3 
Male albino Wistar rats (200–350g) were eu-
thanised by carbon dioxide asphyxiation followed by 
cervical dislocation. The rat tail arterial smooth mus-
cle was prepared and bathed in ice-cold 95% O2/5% 
CO2 oxygenated Krebs’ solution (NaCl 118mM, KCl 
4.7mM, NaHCO3 25mM, NaH2PO4 1.15mM CaCl2 
2.5mM, MgCl2 1.1mM, glucose 5.6mM). Muscle strips, 
2-6mm length, were dissected from rat tail artery and 
connected to a triangular hook which was attached to 
a thread. The smooth muscle preparations were in-
serted onto the tension transducer in 37°C oxygenated 
Krebs’ solution environment. A tension of 0.5g was 
applied to vessel preparations. The smooth muscle 
was pre-treated with phenylephrine (1×10-5M) for 10 
min to achieve constriction plateaux after equilibra-
tion, then separate dose-response curves were con-
structed for BK and the novel peptide using concen-
trations of both peptides in the range of 1×10-11 to 
1×10-5M. The potential BK inhibitory property of the 
novel peptide was measured by prior addition of 
AcT-3 (1×10-6M) to a subsequent dose-response study 
with BK (1×10-11M to 1×10-5M). Changes in tension of 
the tail artery smooth muscle preparations were rec-
orded and amplified through pressure transducers 
connected to a PowerLab System.  
For rat small intestinal smooth muscle prepara-
tions, 1 cm segments of small intestinal were cut and 
placed onto the force transducer. The muscle seg-
ments were exposed to gradually increments of rest-
ing tension until it reached 0.5g. The contracting 
muscle preparations were allowed to stabilize for 20 
min before the application of peptides. The small in-
testinal smooth muscle preparations were exposed to 
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peptides in the concentration range of 1×10-5M to 
1×10-11M, and relative changes in tension were rec-
orded. Six replicates for each experimental data point 
were performed. 
Determination of inhibitory activity on pros-
tate cancer cell lines 
The inhibitory activity of AcT-3 on three differ-
ent prostate cancer lines was measured by MTT assay. 
Briefly, PC3, LNCaP and DU145 cells were seeded 
into 96-well plates at a density of 5,000 cells per well 
and then placed into the cell incubator. On next day, 
the culture medium was refreshed with the same 
value of serum-free RPMI 1640 medium. After 24 h, 
the test concentrations from 1μM to 100μM of AcT-3 
solutions were added to replace the culture medium. 
Paclitaxel (1μM) was used as a positive control to 
compare the anti-proliferative effect of peptide. 20μL 
of MTT was added to each sample after 24, 48 and 72h 
treatment. Four hours later, the absorbance of samples 
(A550) was measured by microplate spectrophotom-
eter (BIO-RAD iMark, USA). Experiments were re-
peated three times in six replicates. 
Cell Death ELISA 
Cell Death ELISA is an enzyme-linked immu-
noassay used for quantification of histone-complex 
DNA fragments out of the cytoplasm of cells after the 
induction of apoptosis or when released from necrotic 
cells, which is also used for distinguishing the two cell 
death mechanisms of necrosis and apoptosis. Here, 
this assay was performed to distinguish the anticancer 
mechanism of AcT-3 by using a Cell Death Detection 
ELISAPLUS Kit (Roche, Germany). Briefly, 100μL of 
Prostate cancer cells (PC3/DU145/LnCap) suspen-
sion were seeded into 96-well plates. After 24 h, a 
range of concentrations of AcT-3 were added to the 
cells after removing the old medium. After further 4h 
incubation, 50µL of the supernatant in each well was 
collected and stored at 4°C. The plate was further in-
cubated for 16 h and then centrifuged to remove the 
supernatant. The cell pellet was resuspended in 200μL 
lysis buffer and 20µL of cell lysate with 80µl immu-
noreagent were added into the streptavidin-coated 
microplate and incubated for 2 h on an MP shaker. 
Then, 100µL of substrate solution was added to mi-
croplate which was washed by incubation buffer and 
the plate was shaken at 100rpm for 10-20min until the 
colour of solution became green or dark green. At last, 
100µL of ABTS stop solution was added to stop the 
reactions. The amount of colour product was meas-
ured using the microplate spectrophotometer. 
Safety evaluation of AcT-3 by haemolytic assay 
The fresh horse blood was centrifuged at 120×g 
for 5 min at room temperature with the cell pellet be-
ing washed three times in PBS solution until the su-
pernatant was clear and then resuspended in PBS 
buffer to give a final cell concentration of 2%. A range 
of concentrations of peptides were dissolved in PBS 
and added into 2mL of red blood cell suspension then 
incubated at 37°C for 2h. 100µL of the supernatants 
was transferred into the 96-well plate to measure the 
haemolytic activity. The plate was read on an ELISA 
reader BIO-RAD iMark, USA) at A550.  
Results  
Molecular cloning of AcT-3 precursor- 
encoding cDNA from the library  
From the Agalychnis callidryas skin ex-
tract-derived cDNA library, a novel tryptophyllin 
peptide (named AcT-3) precursor-encoding cDNA 
was consistently and cloned repeatedly for six times. 
The average size of the DNA inserts is about 300bp 
length. The precursor-encoding cDNA contained an 
open reading frame of 63 amino acid residues. The 
putative signal peptide was typically followed by a 
domain rich in acidic amino residues and containing 
classical processing sites (-R-R-) (Fig. 1A). Mature 
AcT-3 exhibited a high degree of primarily structural 
similarity with the homologue, PhT-3, from the skin 
of the orange-legged leaf frog, Phyllomedusa hypo-
chondrialis, showing 73% sequence identity (Fig. 1B). 
Their open-reading frames both consisted of 63 amino 
acid residues. Such similarity between AcT-3 and 
PhT-3 indicates that they belong to the same peptide 
family and probably have arisen from a common an-
cestral gene. 
Isolation and characterisation of the novel 
peptide, AcT-3 
The proposed putative tridecapeptide, AcT-3, 
was identified following reverse-phase HPLC frac-
tionation of Agalychnis callidryas skin secretion (Fig. 
2A) at the elution time of 33 mintues. MALDI-TOF 
analysis of this fraction, indicated a single peptide 
with an m/z of 1538.19 and a high degree of puri-
ty>80% (Fig. 2B). MS/MS fragmentation sequencing 
of this doubly charged ion (m/z 796.88) (Fig. 3A), 
produced two connective sequence: pEGKPYWP and 
WPPPFLP (Fig. 3B). Therefore, the primary structure 
of the peptide was established by a combination of 
molecular cloning and mass spectrometry as: 
pEGKPYWPPPFLPE. The mature peptide showed the 
N-terminal pGlu formation from Gln after 
post-translational modification. This peptide was 
named, AcT-3, based on its sequence similarity to 
tryptophyllin-3 peptides, which includes tridecapep-
tides and which possess a conserved internal 
-Pro-Pro-Pro-Ile-Tyr-Pro- motif [20].  
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Following obtaining the unequivocal structure, 
AcT-3 was successfully synthesised by using a PS3 
solid phase peptide systhesier and purified using re-
verse phase HPLC to >95% purity.  
Pharmacological effects of AcT-3 on rat 
smooth muscle preparations 
The synthetic AcT-3 induced a slight constriction 
of rat tail artery smooth muscle preparations with an 
EC50 value of 3.2×10-9M. BK was proven to induce rat 
tail artery smooth muscle relaxation in a previous 
report [24]. Here, BK was found to significantly relax 
rat tail artery smooth muscle preparations with an 
EC50 of 12.1×10-6M (Fig. 4A). The optimal relaxation 
was noted at 10-6M, with a relaxation magnitude of 
59.48%±1.43%. Pre-incubation of rat tail artery smooth 
muscle with 1×10-6M AcT-3 (the most effective con-
centration) reduced artery relaxation induced by BK 
(Fig. 4B). The maximal relaxation induced by 1x10-6M 
BK was reduced to 12.8% ±0.11, which was almost an 
eighty percent decrease compared to when the 
smooth muscle was treated with BK alone.  
Application of the synthetic AcT-3 peptide to rat 
small intestinal in the concentration range of 1×10-11 to 
1×10-5M, confirmed it has the contracting effect on this 
tissue with EC50 value of 2.2×10-8M (Fig.4C). The op-
timal contraction was at 1×10-6M, with a contracting 
magnitude of 40.28%±4.39%. Thus it can be seen, alt-
hough AcT-3 showed pharmacological effects on both 
rat tail artery and small intestinal smooth muscle 
preparations, but the effects are totally different. 
 
 
Figure 1. (A) Nucleotide sequence of frog skin-derived cDNA encoding the biosynthetic precursor of AcT-3. The putative signal peptide marked with double-underline, mature 
peptide marked with single-underline and stop codon (asterisk) is indicated. (B) Alignments of open-reading frame amino acid sequences of AcT-3 and PhT-3. The main structure 
of the precursors is indicated. (1) Putative signal peptide. (2) Acidic spacer peptide. (3) Mature peptide. (4) C-terminal processing site. Conserved residues are indicated by 
asterisks. 
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Figure 2. (A) Reversed phase HPLC separation of skin secretion components from Agalychins callidryas. The absorbance was monitored at 214nm. The retention times of AcT-3 
was indicated by arrows. (B)MALDI-TOF mass spectrogram of AcT-3 (m/z=1538.19) from a reverse phase HPLC fraction of the frog skin secretion. 
 
The cancer inhibitory activity of AcT-3 
To determine the cancer cell anti-proliferative 
effects of AcT-3, human prostate cancer cells 
(LNCap/PC3/DU145), were incubated in a range 
concentrations of AcT-3 for 72h. The cell viability was 
measured by MTT assay. PTX used as a positive con-
trol could significantly inhibit all three prostate cancer 
cell lines. For AcT-3, the inhibitory effect on PC3 cells 
was more obviously than the other two cell lines. The 
effect of the peptide on the growth of andro-
gen-dependent prostate cancer LNCaP cells is shown 
in Fig. 5(A-C). The results suggest that the peptide 
could inhibit the cells at the highest concentration 
employed and the inhibitory effect decreased follow-
ing the time. When the concentration of AcT-3 was 
100µM, the cell viability of LNCaP cells was 
57.66%±7.40% after 24h, 79.69%±5.55% after 48h and 
79.13%±6.67% after 72h, compared with the control 
conditions. Fig.5 (D-F) shows the effect of AcT-3 on 
the growth of androgen-independent prostate cancer 
PC3 cells and this peptide could inhibit PC3 cell 
growth at concentrations from 1µM to 100µM. At the 
optimal anti-growth concentration (100µM), after 24h, 
cell viability was 78.53%±6.10%; after 48h, cell viabil-
ity was 64.06%±4.18%; after 72h, cell viability was 
58.73%±9.79%, compared to the control conditions. 
The inhibitory effect increased following the time on 
this cell line. The anti-proliferative effect of AcT-3 
towards human androgen-independent DU145 cells is 
shown in Fig. 5(G-I). AcT-3 inhibited DU145 cells 
proliferation at concentrations from 1µM to 100µM. 
Following treatment of DU145 cells with 100µM 
AcT-3, the cell viability was reduced to 77.45%±4.19% 
after 24h, 79.56%±3.96% after 48h and 80.24%±7.94% 
after 72 h, compared with the control conditions.  
Cell Death ELISA 
To determine the role of cell death in the an-
ti-proliferative process of AcT-3, DNA fragmentation 
was measured by using the cell death ELISA. The 
assay carried out at 4h was to capture the rapid-
ly-induced process of apoptosis and measured at 16h 
was to get the result of longer-term induction of ne-
crosis. 
As shown in Fig. 6, after 4h, DNA fragmentation 
did not appear to have occurred in any cancer cells as 
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no increase in absorbance was observed within the 
lysates or the supernatants (data not shown). After 
16h, DNA fragmentation was observed both in the 
lysates and the supernatants of all three cell lines. 
Increased DNA fragments in the cell supernatants 
were significantly higher than in the cell lysates, 
which meant that the plasma membrane had been 
ruptured causing release of the mono- and oligonu-
clesomes into the cytoplasm. The absorbance of the 
cell supernatants corresponds to the increase number 
of dead cells increased with AcT-3 concentrations 
after 16h, which means that AcT-3 induced prostate 
cancer cell death through the mechanism of necrosis 
pathway. 
Safety evaluation of AcT-3 by haemolytic assay 
These results demonstrated that AcT-3 showed 
no lytic activity on horse erythrocytes in the investi-
gated concentrations (Fig. 7), which meant AcT-3 had 
no obvious cytotoxic effect. 
 
 
 
Figure 3. (A) Solarix FT-ICR-MS full scan of AcT-3 from reverse phase HPLC fraction. The doubly charges ion (m/z 769.88), triply charged ion (m/z 526.24) of a peptide with 
parent mass of 1539.79Da were detected. (B) MS/MS fragmentation spectrum of doubly charged ion (m/z 769.88). 
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Figure 4. (A) Dose-response curves of Bradykinin (●) and AcT-3 (■) in rat tail artery 
smooth muscle preparations. (B) Dose response of BK in the rat tail artery smooth 
muscle (●) and BK dose response in AcT-3 pre-incubated (10-6M) artery smooth 
muscle (■). (C) Dose-response curves of AcT-3 (●) in rat small intestinal smooth 
muscle preparations. Error bars indicate the mean±SEM. Six replicates of each point 
were recorded. 
 
Discussion 
Amphibian skin is a rich source of biological-
ly-active compounds that are assumed to have diverse 
physiological and defence functions. In the range of 
bioactive peptides, some of have antimicrobial effects 
against a broad spectrum of bacterial species and 
others are pharmacologically-active, many of these 
having endogenous mammalian homologues [23]. To 
date, many pharmacologically-active peptides have 
been studied from various species of frogs, especially 
from the sub-family Phyllomedusinae. The red-eyed 
leaf frog, Agalychnis callidryas, that was investigated 
here, also belongs to this frog sub-family and alt-
hough this species is readily available in the herpe-
tology pet trade due to its striking beauty and relative 
ease of captive breeding, few studies have been re-
ported on the compounds isolated from its defensive 
skin secretions [24]. A preliminary study of Agalychnis 
species suggested that they contained bioactive pep-
tides which are similar to the peptides identified from 
other phyllomedusine frogs [13]. Five peptide families 
have been identified previously in methanol extracts 
of the skin of A. callidryas, namely a caerulein, a 
phyllokinin, several tachykinins, an opioid peptide 
and sauvagine [25].  
Tryptophyllins are a group of amphibian skin 
peptides widespread in frogs of the hylid genera, 
Phyllomedusa and Litoria [14]. This is a group of small 
peptides, containing four to fourteen amino acid res-
idues, with a common tryptophan (Trp) residue in 
their structures. They were first identified in and iso-
lated from methanol extracts of Phyllomedusa rohdei 
skin [26] and since then, a number of TPHs have been 
discovered from the skins of many hylid species [14]. 
Two TPHs, PdT-1 (KPHypAWVPV-NH2) and PdT-2 
(DMSPPWH-NH2), isolated from the skin of the 
phyllomedusine frog, Pachymedusa dacnicolor, by Chen 
et al in 2004, exhibit smooth-muscle activity [24]. A 
Tryptophyllin type two peptide recently identified 
from A. callidryas showed myotropic and antimicro-
bial activities [27]. One of TPHs (FPPWM-NH2) dis-
covered by Erspamer, induces sedation and behav-
ioural sleep in birds and is also immunoreactive to a 
set of cells in the rat adenohypophysis [13]. 
Here, a novel TPH peptide, named AcT-3, iso-
lated from skin secretion of A. callidryas, is described. 
Synthetic replicates of AcT-3 were found to attenuate 
the bradykinin-induced relaxation response in rat 
arterial smooth muscle and to contract rat small in-
testinal smooth muscle preparations. AcT-3 also 
showed anticancer effect on three types of human 
prostate cancer lines. The peptide-containing fraction 
was separated from a complex mixture of peptidic 
components by reverse-phase HPLC and then ana-
lysed by MALDI-TOF mass spectrometry to obtain 
the molecular mass estimate of 1538.19Da. MS/MS 
fragmentation of the peptide unequivocally estab-
lished the primary structure of a proline-rich peptide 
whose computed molecular mass was very similar to 
the one obtained by mass spectrometry. The peptide 
was classified by searching a group of structural-
ly-similar peptides through an NCBI Blast search 
which revealed that AcT-3 belonged to the T-3 group 
of the TPH family. 
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Figure 5. AcT-3 inhibits the proliferation of androgen-dependent prostate cancer LNCaP cells and androgen-independent prostate cancer PC3 and DU145 cells in 72h. LNCaP 
cells were treated with AcT-3 and incubated for 24h (A), 48h (B) and 72h (C). PC3 cells were treated with AcT-3 and incubated for 24h (D), 48h (E) and 72h (F). DU145 cells 
were treated with AcT-3 and incubated for 24h (G), 48h (H) and 72h (I). Statistical analysis was performed using Student’s t-test. Data shown represents mean±SEM of three 
separate experiments. Six replicates were recorded in each experiment. Asterisks indicate *p<0.05, **p<0.01, ***p<0.001 versus controls. 
 
The presence of this peptide was further con-
firmed by the fact that it was found to be encoded by a 
discrete biosynthetic precursor whose structure was 
deduced from a cDNA that was cloned from a dried 
skin extract-derived cDNA library of A. callidryas. The 
open-reading frame of AcT-3 exhibited a high degree 
of similarity with a previously-discovered peptide, 
PhT-3 from P. hypochondrialis. The organisation of the 
biosynthetic precursor of AcT-3 is typically that ob-
served for many amphibian skin peptides in that it 
can be generally considered to have four major se-
quentially-occurring domains. The first encodes a 
putative signal peptide of 22 amino acid residues that 
is usually highly-conserved in structure within a 
given species and often between species [28]. Signal 
peptides are typical of transcripts encoding products 
that are destined for secretion. The second encodes 
another highly-conserved acidic amino acid resi-
due-rich spacer peptide domain whose function is 
unknown but that possibly plays a role in peptide 
storage or packaging within secretory cells. This do-
main consists of a typical propeptide convertase pro-
cessing site (-RR-) located upstream of the mature 
active peptide domain and cleavage of this generates 
the N-terminus of the mature peptide. The third do-
main encodes the mature peptide and by nature is 
usually hypervariable in sequence ensuring product 
diversity from a relatively-conserved biosynthetic 
precursor template. The fourth domain encodes the 
C-terminal processing site.  
A synthetic replicate of AcT-3 tested in this study 
was found to antagonise the effect of BK on artery 
smooth muscle in a manner that suggested a 
non-competitive mode of action. This effect is likely to 
extend to other T-3 peptides from other species, espe-
cially from the phyllomedusinae sub-family. PhT-3 
from P. hypochondrialis, is a structural homologue of 
AcT-3 and exhibits the same pharmacological effect in 
the rat tail artery.  
Prostate cancer is one of the most commonly 
diagnosed cancers and the second leading cause of 
cancer deaths in males [31]. In the study of prostate 
cancer therapeutics, some representative prostate 
cancer cell lines have been established to investigate 
prostate cancer in vitro, the most widely used cells are 
three kinds of cell lines (LNCaP, PC3 and DU145). The 
PC3 and DU145 cells were isolated from human 
prostatic adenocarcinoma metastatic to bone and to 
brain, respectively. The LNCaP cancer cell line was 
established from a human lymph node metastatic 
lesion of prostatic adenocarcinoma. LNCaP cells are 
androgen-dependent prostate cancer cell lines, which 
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express the androgen receptor. LNCaP cells will only 
grow in an androgen-containing environment. In 
contrast, PC3 and DU145 cells express very little or no 
AR, so the proliferation of PC3 or DU145 is not an-
drogen dependent [32, 33]. We choose these cell lines 
as in vitro prostate cancer model to examine the anti-
cancer effect of AcT-3. Prostate cancer shares with 
lung cancer a common origin in neuro-endocrine cells. 
These cells bear receptors for growth factor neuro-
peptides, such as BK and bombesin. Thereinto, BK has 
a role to play in the progress of prostate cancer [29] 
and both BK receptors (B1 and B2) are demonstrated 
to express in prostate cancer cells [30-31, 34]. The re-
ceptors on prostate cancer can bind with growth fac-
tor neuropeptides, and effectively stimulate cancer 
cell growth and production of the congeneric peptides 
[35]. BK antagonists thus have a great potential to be 
developed as anticancer drugs. The experimental de-
sign used here was to determine the anticancer effect 
of AcT-3, which has BK antagonism effects in artery 
smooth muscle. The results showed that AcT-3 treat-
ment, dose-dependently inhibited the proliferation of 
human prostate cancer cell lines, LNCaP, PC3 and 
DU145, over 72h. The antagonism effect on cancer 
cells is not as obviously as that on smooth muscle, 
which indicates that the same peptide may have a 
different binding ability with the same receptor in 
different tissues. Besides BK, there are many other 
cancer growth factors like Tyrosine kinases GRB2, 
EGF and IGF-I [36], so blocking the effect of BK may 
just partly inhibit cancer cell proliferation. It remains 
unclear whether AcT-3 acts at one or both of the BK 
receptors, and thus it cannot be stated indisputably 
whether antagonism is occurring at the B1 or the B2 
receptor, or at both receptors in these cancer cell lines. 
At last, haemolytic assay is performed as a safety 
evaluation on the effect of peptides on a standardized 
model of mammalian cells. Here, we use erythrocytes 
as a representative to determine the cytotoxic/lytic 
effects of individual peptides. The results demon-
strated that AcT-3 had no observable lytic effects on 
normal cells. 
 
 
Figure 6. Detection of DNA fragmentation in the cell cytoplasm of human prostate 
cancer cell lines (A: LNCap; B: PC3; C: DU145) treated with AcT-3. Three replicates 
at each point were recorded. 
 
 
Figure 7. Haemolytic effect of AcT-3. Three replicates at each point were recorded. 
(Positive control: 2% red cell suspension + equal volume PBS containing 2% Tri-
ton-100; Negative control: 2% red cell suspension + equal volume PBS). 
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Assay; PBS: Phosphate Buffer Solution; TFA: tri-
fluoroacetic acid. 
Int. J. Biol. Sci. 2015, Vol. 11 
 
 
http://www.ijbs.com 
219 
Acknowledgements: 
This work was supported by a grant from Na-
tional Natural Science Foundation of China (No. 
81402901), Tianjin Education Commission of China 
(No. 20120136) and China Postdoctoral Science 
Foundation (No. 2014M551035). 
Author contribution 
TB Chen and C Shaw conceived and designed 
the experiments, R Wang and Y Zhou Performed the 
experiment, R Wang wrote the manuscript, L Wang 
and M Zhou coordinated and directed the manuscript 
writing.  
Competing Interests 
The authors have declared that no competing 
interest exists. 
References 
1.  Savage JM. The Amphibians and Reptiles of Costa Rica: a herpetofauna be-
tween two continents, between two seas. Salt Lake City, United States: Uni-
versity of Chicago Press books. 2002:122-158. 
2.  Clark BT. The natural history of amphibian skin secretions, their normal 
function and potential medicinal applications. Biological Reviews of the 
Cambridge Philosophical Society. 1997; 72: 365-379. 
3.  Toledo RC and Jared C. Cutaneous granular glands and amphibian ven-
oms. Comparative Biochemistry and Physiology Part A: Physiology. 1995; 111: 
1-29. 
4.  Elkan E. Mucopolysaccarides in the anuran defence against dessication. 
Journal of Zoology. 1968; 155: 9-53. 
5.  Bevins CL and Zasloff M. Peptides from frog skin. Annual Review of Bio-
chemistry. 1990; 59: 395-414. 
6.  Gomes A, Giri B, Saha A, Mishra R, Dasgupta SC, Debnath A, Gomes A. 
Bioactive molecules from amphibian skin: their biological activities with ref-
erence to therapeutic potentials for possible drug development. Indian J Exp 
Biol. 2007; 45: 579-593. 
7.  Li J, Xu X, Xu C, Zhou W, Zhang K, Yu H, Zhang Y, Zheng Y, Rees HH, Lai R, 
Yang D, Wu J. Anti-infection peptidomics of amphibian skin. Mol Cell Pro-
teomics. 2007; 6: 882-894. 
8.  Nascimento AC, Fontes W, Sebben A, Castro MS. Antimicrobial peptides from 
anurans skin secretions. Protein and Peptide Letters. 2003;10: 227-238. 
9.  VanCompernolle SE, Taylor RJ, Oswald-Richter K, Jiang J, Youree BE, Bowie 
JH, Tyler MJ, Conlon JM, Wade D, Aiken C, Dermody TS, KewalRamani VN, 
Rollins-Smith LA, Unutmaz D. Antimicrobial peptides from amphibian skin 
potently inhibit human immunodeficiency virus infection and transfer of virus 
from dendritic cells to T cells. J Virol. 2005; 79(18):11598-11606. 
10.  Chinchar VG, Bryan L, Silphadaung U, Noga E, Wade D, Rollins-Smith L. 
Inactiviation of viruses infecting ectothermic animals by amphibian piscine 
antimicrobial peptides. Virology. 2004; 323: 268-275. 
11.  Apponyi MA, Pukala TL, Brinkworth CS, Maselli VM, Bowie JH, Tyler MJ, 
Booker GW, Wallace JC, Carver JA, Separovic F, Doyle JR and Llewellyn L. 
Host-defence peptides of Australian anurans: structure, mechanism of action 
and evolutionary significance. Peptides. 2004; 25: 1035-1054.  
12.  Gibson BW, Poulter L, Williams DH, Maggio JE. Novel peptide fragments 
originating from PGLa and the caerulein and xenopsin precursors from 
Xenopus laevis. J. Biol. Chem. 1986; 261: 5341-5534. 
13.  Erspamer V, Melchiorri P, Erspamer FG, Montecucchi PC, De Castiglione R. 
Phyllomedusa skin, a huge factory and store-house of a variety of active pep-
tides. Peptides. 1985; 6: 7–12. 
14.  Bowie JH and Tyler MJ. Host defense peptides from Australian amphibians: 
Caeruliein and other neuropeptides. Handbook of biologically active peptides. 
2006; 43: 283-289. 
15.  Brand GD, Krause FC, Silva LP, Leite JRSA, Melo JAT, Prates MV, Pesquero 
JB, Santos EL, Nakaie CR, Costa-Neto CM, Bloch C Jr. Bradykinin-related 
peptides from Phyllomedusa Hypochondrialis. Peptides. 2006; 27: 2137-2146. 
16.  Erspamer V, Erspamer FG, Cei JM. Active peptides in the skins of two hun-
dred and thirty American amphibian species. Comp Biochem Physiol C. 1986; 
85: 125-137. 
17.  Rates B, Silva LP, Ireno IC, Leite FSF, Borges MH, Bloch C Jr., De Lima ME, 
Pimenta AM. Peptidomic dissection of the skin secretion of Phasmahyla jan-
daia. Toxicon. 2011; 57: 35-52. 
18.  Conlon JM, Jouenne T, Cosette P, Cosquer D, Hubert Vaudry, Christopher K. 
Abel T, Abel PW. Bradykinin-related peptides and tryptophyllins in the skin 
secretions of the most primitive extant frog, Ascaphus truei. General and 
Comparative Endocrinology. 2005; 143: 193-199. 
19.  Langsdorf M, Ghassempour A, Rompp1 A, Spengler B. Characterization of a 
peptide family from the skin secretion of the Middle East Tree Frog Hyla sa-
vignyi by composition-based de novo sequencing Rapid Commun. Mass 
Spectrom. 2010; 24: 2885–2899. 
20.  Chen TB, Walker B, Zhou M, Shaw C. Dermatoxin and phylloxin from the 
waxy monkey frog, Phyllomedusa sauvagei: Cloning of precursor cDNAs and 
structural characterization from lyophilized skin secretion. Regulatory Pep-
tides. 2005; 129: 103-108. 
21.  Ruiz-Carranza PM, Ardila-Robayo MC, Lynch JD. Lista actualizada de la 
fauna de Amphibia de Colombia. Revista de la Academia Colombiana de 
Ciencias Exactas. Ficasy Naturales. 1996; 20: 365-415. 
22.  Amiche M, Ladram A, Nicolas PA. Consistent nomenclature of antimicrobial 
peptides isolated from frogs of the subfamily Phyllomedusinae. Peptides. 
2008; 2: 2074-2082. 
23.  Barra D, Simmaco M. Amphibian skin: a promising resource for antimicrobial 
peptides. Trends Biotechnol. 1995; 13: 205–209. 
24.  Wang L, Zhou M, Chen T, Walker B, Shaw C. PdT-2: A novel myotropic 
Type-2 tryptophyllin from the skin secretion of the Mexican giant leaf frog, 
Pachymedusa dacnicolor. Peptides. 2009; 30: 1557–1561. 
25.  Mignogna G, Pascarella S, Wechselberger C, Hinterleitner C, Mollay C, 
Amiconi G, Barra D, Kreil G. BSTI, a trypsin inhibitor from skin secretions of 
Bombina bombina related to protease inhibitors of nematodes. Protein Sci. 
1996; 5: 357–362.  
26.  Montecucchi PC. Isolation and primary structure determination of amphibian 
skin tryptophyllins. Peptides. 1985; 6: 187–195. 
27.  Ge L, Lyu P, Zhou M, Zhang H, Wang Y, Li B, Li R, Chen T, Shaw C. AcT-2: a 
novel myotropic and antimicrobial type 2 tryptophyllin from the skin secre-
tion of the Central American red-eyed leaf frog, Agalychnis callidryas. Scien-
tificWorldJournal. 2014; 2014: 176214. 
28.  Vanhoye D, Bruston F, Nicolas P, Amiche M. Antimicrobial peptides from 
hylid and ranin frogs originated from a 150-million-year-old ancestral pre-
cursor with a conserved signal peptide but a hypermutable antimicrobial 
domain. Eur.J. Biochem. 2003; 70: 2068–2081. 
29.  Papandreou CN, Usmani B, Geng YP, Bogenrieder T, Freeman R, Wilk S, 
Finstad CL, Reuter VE, Powell CT, Scheinberg D, Magill C, Scher HI, Albino 
AP, Nanus DM. Neutral endopeptidase 24.11 loss in metastatic human pros-
tate cancer contributes to androgen-independent progression. Nat Med. 1998; 
4: 50–57. 
30.  Srinivasan D, Burbach LR, Daniels DV, Ford W, Bhattacharya A. Pharmaco-
logical characterization of canine bradykinin receptors in prostatic culture and 
in isolated prostate. Br J Pharmacol. 2004; 142: 297–304. 
31.  Taub JS, Guo R, Leeb-Lundberg LMF, Madden JF, Daaka Y. Bradykinin Re-
ceptor Subtype 1 Expression and Function in Prostate Cancer. Cancer research. 
2003; 63: 2037–2041. 
32.  Kokontis JM, Hsu S, Chuu CP, Dang M, Fukuchi J, Hiipakka RA, Liao S. Role 
of androgen receptor in the progression of human prostate tumor cells to an-
drogen independence and insensitivity. The Prostate. 2005; 65: 287–298. 
33.  Umekita Y, Hiipakka RA, Kokontis JM, Liao S. "Human prostate tumor 
growth in athymic mice: inhibition by androgens and stimulation by finas-
teride". Proc. Natl. Acad. Sci. U.S.A. 1996; 93: 11802–11807. 
34.  Barki-Harrington L, Bookout AL, Wang GF, Lamb ME, Leeb-Lundberg LM, 
Daaka Y. Requirement for direct cross-talk between B1 and B2 kinin receptors 
for the proliferation of androgen-insensitive prostate cancer PC3 cells. Bio-
chem. J. 2003; 371:581-587. 
35.  Stewart JM, Gera L, Chan DC, Bunn Jr PA, York EJ, Simkeviciene V, Helfrich 
B. Bradykinin-related compounds as new drugs for cancer andinflammation. 
Can J Physiol Pharm. 2002; 80: 275– 280. 
36.  Rajkumar T. Growth factors and growth factor receptors in cancer. Current 
science. 2001; 8: 535-541. 
